Tokyo, July 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062106) titled 'Establishment of novel cohort to define preclinical rheumatoid arthritis (TATEYAMA [Tracking Arthritis Through Early Yield And Monitoring in Advance] cohort study)' on July 1.
Study Type:
Observational
Primary Sponsor:
Institute - University of Toyama
Condition:
Condition - preclinical and very early rheumatoid arthritis.
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Characterise preclinical/very early rheumatoid arthritis.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - adult individuals who visited the clinic with joint pain as the chief complaint, or those who were found to be positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibodies during health checkups or medical screenings, but do not meet the ACR/EULAR classification criteria for RA (Aletaha D, et al. Ann Rheum Dis. 2010 Sep;69(9):1580-8).
Key exclusion criteria - Individuals who have been diagnosed with RA, rheumatic diseases, or collagen diseases and are currently undergoing or have previously undergone treatment.
Target Size - 500
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 03 Month 26 Day
Date of IRB - 2025 Year 03 Month 26 Day
Anticipated trial start date - 2025 Year 04 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064888
Disclaimer: Curated by HT Syndication.
